Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

A Multicenter, Randomized, Sham-controlled, Repeat-dose Study to Assess the Safety, Tolerability, Serum Pharmacokinetics, and Efficacy of Intravitreal LFG316 in Patients With Neovascular Age-related Macular Degeneration

Authors not listed

Novartis Pharmaceuticals · 2012

Abstract

This study will assess the safety and efficacy of LFG316 in patients with age related macular degeneration.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-15 MST

Cite this

APA
Anonymous. (2012). A Multicenter, Randomized, Sham-controlled, Repeat-dose Study to Assess the Safety, Tolerability, Serum Pharmacokinetics, and Efficacy of Intravitreal LFG316 in Patients With Neovascular Age-related Macular Degeneration. <em>Novartis Pharmaceuticals</em>. https://clinicaltrials.gov/study/NCT01535950
Vancouver
Anonymous. A Multicenter, Randomized, Sham-controlled, Repeat-dose Study to Assess the Safety, Tolerability, Serum Pharmacokinetics, and Efficacy of Intravitreal LFG316 in Patients With Neovascular Age-related Macular Degeneration. Novartis Pharmaceuticals. 2012.
BibTeX
@misc{anon2012AMulti, title = {A Multicenter, Randomized, Sham-controlled, Repeat-dose Study to Assess the Safety, Tolerability, Serum Pharmacokinetics, and Efficacy of Intravitreal LFG316 in Patients With Neovascular Age-related Macular Degeneration}, author = {Anonymous}, journal = {Novartis Pharmaceuticals}, year = {2012}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings